Pancreatic Cancer Research

ResearcherNew York UniversityNo recent work listed

J. Marc Pipas

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0009-0005-9972-5451; OpenAlex author ID A5086314355. Sources: ClinicalTrials.gov.

Their work

Papers
11 (first author 0, last author 2)
Trials
3 (principal investigator on 3)
Grants
0
Labs led
1
Collaborators
44
Papers, trials and grants by year

2004: 1 trial · 2005: 1 trial · 2006: none · 2007: none · 2008: 1 trial · 2009: none · 2010: none · 2011: 2 papers · 2012: 1 paper · 2013: 2 papers · 2014: 1 paper · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: 2 papers

Papers 11

  1. Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine i… Co-author DOI 10.1016/j.annonc.2019.09.004↗
  2. Corrigendum to 'Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel a… Co-author DOI 10.1016/j.annonc.2020.05.011↗
  3. Dual Inhibition of IGF-1R and ErbB3 Enhances the Activity of Gemcitabine and Nab-Paclitaxel in Preclinical Models of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-2262↗
  4. Nanoliposomal Irinotecan in the Clinical Practice Guideline for Metastatic Pancreatic Cancer: Applicability to Clinical Situations. Co-author DOI 10.1200/jco.2016.70.1607↗
  5. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Ther… Co-author DOI 10.1200/jco.2015.61.4578↗
  6. The effect of neoadjuvant chemoradiation on pancreatic cancer-associated diabetes mellitus. Last author DOI 10.1097/mpa.0000000000000162↗
  7. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm. Co-author DOI 10.1016/j.cancergen.2013.05.020↗
  8. Successful retreatment with chemoradiotherapy for local recurrence of pancreatic adenocarcinoma after neoadjuvant therapy and pancreaticoduodenectomy. Last author PMID 24147160↗
  9. Neoadjuvant cetuximab, twice-weekly gemcitabine, and intensity-modulated radiotherapy (IMRT) in patients with pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mds109↗
  10. Screening for pancreatic cancer in a high-risk population with serum CA 19-9 and targeted EUS: a feasibility study. Co-author DOI 10.1016/j.gie.2011.03.1235↗
  11. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-11-0695↗

Trials 3

  1. A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreati… Principal investigator NCT01181245↗
  2. Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer Principal investigator NCT00225784↗
  3. Ghrelin Levels in Pancreatic Cancer Patients Principal investigator NCT00225745↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Johanna C. Bendell · 3 shared papers, 2015–2020 · strength 0.22
  2. Stuart R. Gordon · 6 shared papers, 2011–2014 · strength 0.19
  3. Andrew H. Ko · 2 shared papers, 2020 · strength 0.18
  4. Syed Farhan Zafar · 2 shared papers, 2020 · strength 0.18
  5. Fernando Rivera · 2 shared papers, 2020 · strength 0.18
  6. David J. Watkins · 2 shared papers, 2020 · strength 0.18
  7. Uwe Pelzer · 2 shared papers, 2020 · strength 0.18
  8. Hana Algül · 2 shared papers, 2020 · strength 0.18
  9. Madappa N. Kundranda · 2 shared papers, 2020 · strength 0.18
  10. Gregory J. Tsongalis · 4 shared papers, 2012–2014 · strength 0.13
  11. Arief Antonius Suriawinata · 4 shared papers, 2012–2014 · strength 0.13
  12. Timothy B. Gardner · 4 shared papers, 2011–2014 · strength 0.12
  13. Bassem I. Zaki · 3 shared papers, 2012–2014 · strength 0.10
  14. Richard J. Barth · 3 shared papers, 2012–2014 · strength 0.10
  15. Bruce Belanger · 1 shared paper, 2017 · strength 0.08
  16. Li‐Tzong Chen · 1 shared paper, 2017 · strength 0.08
  17. Jens Thomas Siveke · 1 shared paper, 2017 · strength 0.08
  18. Richard A Hubner · 1 shared paper, 2017 · strength 0.08
  19. Andrea Wang‐Gillam · 1 shared paper, 2017 · strength 0.08
  20. Daniel D. Von Hoff · 1 shared paper, 2017 · strength 0.08
  21. Adam J. Camblin · 1 shared paper, 2018 · strength 0.06
  22. Chrystal Ursula Louis · 1 shared paper, 2018 · strength 0.06
  23. Alexey A. Lugovskoy · 1 shared paper, 2018 · strength 0.06
  24. Robert M. Straubinger · 1 shared paper, 2018 · strength 0.06
  25. Kerrington D. Smith · 2 shared papers, 2012–2014 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.